In a filing, Pyxis Oncology Inc revealed its CFO & COO Connealy Pamela Ann acquired Company’s shares for reported $0.17 million on Nov 26 ’24. In the deal valued at $1.96 per share,88,850 shares were bought. As a result of this transaction, Connealy Pamela Ann now holds 1,199,143 shares worth roughly $2.4 million.
William Blair downgraded its Pyxis Oncology Inc [PYXS] rating to a Mkt perform from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including Stephens’s analysts, who began to cover the stock in early November with a ‘”an Overweight”‘ rating. Stifel began covering PYXS with “Buy” recommendation on August 08, 2024.
Price Performance Review of PYXS
On Monday, Pyxis Oncology Inc [NASDAQ:PYXS] saw its stock fall -0.50% to $2.00. Over the last five days, the stock has gained 5.26%. Pyxis Oncology Inc shares have risen nearly 11.11% since the year began. Nevertheless, the stocks have risen 25.79% over the past one year. While a 52-week high of $6.85 was reached on 02/27/24, a 52-week low of $1.56 was recorded on 11/27/24. SMA at 50 days reached $3.47, while 200 days put it at $3.97.
Levels Of Support And Resistance For PYXS Stock
The 24-hour chart illustrates a support level at 1.92, which if violated will result in even more drops to 1.85. On the upside, there is a resistance level at 2.08. A further resistance level may holdings at 2.17. The Relative Strength Index (RSI) on the 14-day chart is 28.51, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.12, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 92.28%. Stochastics %K at 5.51% indicates the stock is a buying.
How much short interest is there in Pyxis Oncology Inc?
A steep rise in short interest was recorded in Pyxis Oncology Inc stocks on 2024-11-15, growing by 0.93 million shares to a total of 5.84 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-15 was 4.91 million shares. There was a rise of 15.95%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on February 09, 2024 when BTIG Research began covering the stock and recommended ‘”a Buy”‘ rating along with a $8 price target.
